Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).
HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.
This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.
The FDA chose HERNEXEOS for the CNPV program.
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Cosmo and Glenmark receive European marketing authorisation for Winlevi